Kingfisher share price hits new 52-week high on buyback grind — what to watch next week

Kingfisher share price hits new 52-week high on buyback grind — what to watch next week

February 15, 2026

London, Feb 15, 2026, 15:33 GMT — Market’s done for the day

  • Kingfisher ended the session at 362.5 pence, up 1.65% and touching a new 52-week high.
  • A new regulatory filing shows 1.2 million more shares snapped up for cancellation as part of the £300 million buyback.
  • Eyes are turning to the full-year results due in late March, with investors hunting for clues on trading and cash flow.

Kingfisher Plc (KGF.L) finished Friday at 362.5 pence, notching a fresh 52-week high with a 1.65% gain, just as London markets headed into the weekend closure. Shares in the B&Q and Screwfix parent are sitting at the very top of their 12-month range, which runs from 238.5p up to 362.5p.

This matters for Monday: Kingfisher’s been drip-feeding investors with regular capital-return updates as everyone waits on its next numbers. At these prices, even the usual disclosures are picked apart for clues on confidence and cash flow.

A regulatory filing revealed the group snapped up 1.2 million shares on Feb. 12, paying a volume-weighted average of £3.5575. Prices ranged from £3.5120 at the low end to £3.5890 at the top. The shares came from Goldman Sachs International, as part of Kingfisher’s £300 million buyback plan. These shares are set to be cancelled, trimming the outstanding total.

The math on buybacks looks straightforward: reducing share count tends to boost earnings per share. But in reality, those repurchases spotlight management’s approach to cash. Investors watch to see if companies stick with buybacks when markets start to wobble.

Kingfisher’s most recent market update saw it lift its adjusted pretax profit forecast for the year ending January 2026, bumping the range up to 540 million to 570 million pounds. Previously, guidance had topped out at the upper end of 480 million to 540 million. “We delivered another quarter of high-quality, volume-led growth,” Chief Executive Thierry Garnier said at the time. The company flagged soft consumer sentiment, ongoing political uncertainty, and strike action in France. Reuters

RBC Europe analysts sounded more positive following Kingfisher’s first-half results in September, saying, “We see potential for DIY trends to be fairly resilient.” They also pointed out that the company had sped up its share buyback programme, aiming to finish the process by March 2026. Reuters

Looking to the week, traders are watching for more buyback announcements—a key signal for daily liquidity in the stock. They’ll also be quick to react to fresh UK consumer or housing data, particularly anything that could influence demand in the home improvement sector’s high-value categories like kitchens and bathrooms.

Still, notching a new high comes with higher expectations. If there’s any signal that spring demand is slipping, or France continues to weigh on both margins and volumes, questions about what’s really driving the rally—underlying business strength or just financial moves—could get a lot sharper.

Kingfisher’s next big event lands March 24, with full-year results set to shed light on market-by-market trading, cash flow developments, and how quickly buybacks are moving.

Stock Market Today

  • New Drug Apitegromab May Preserve Muscle Mass During Weight Loss with GLP-1 Injections
    June 8, 2026, 1:35 PM EDT. A muscle growth drug, apitegromab, could reduce loss of lean body mass in patients using weight loss GLP-1 jabs like tirzepatide (Mounjaro), a small US trial shows. Lean mass includes muscle, vital for strength, calorie burning, and diabetes risk reduction. The study involved 102 participants receiving tirzepatide with either apitegromab or placebo over 24 weeks. Apitegromab users lost 55% less lean muscle compared to placebo, despite similar total weight loss. Researchers caution the results are preliminary due to the trial's small size, short duration, and predominantly female cohort. Experts emphasize the need for larger, longer studies to verify safety and functional benefits.